CN1688343B - 修饰糖、其缀合物及其制备方法 - Google Patents

修饰糖、其缀合物及其制备方法 Download PDF

Info

Publication number
CN1688343B
CN1688343B CN038237245A CN03823724A CN1688343B CN 1688343 B CN1688343 B CN 1688343B CN 038237245 A CN038237245 A CN 038237245A CN 03823724 A CN03823724 A CN 03823724A CN 1688343 B CN1688343 B CN 1688343B
Authority
CN
China
Prior art keywords
sugar
group
capsular saccharides
protein
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038237245A
Other languages
English (en)
Chinese (zh)
Other versions
CN1688343A (zh
Inventor
A·吉亚诺齐
G·阿弗拉尼
F·诺莱利
P·科斯坦蒂诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Novartis Vaccines and Diagnostics SRL
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL, Chiron SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of CN1688343A publication Critical patent/CN1688343A/zh
Application granted granted Critical
Publication of CN1688343B publication Critical patent/CN1688343B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN038237245A 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法 Expired - Fee Related CN1688343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
GB0220198.6 2002-08-30
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101825535A Division CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Publications (2)

Publication Number Publication Date
CN1688343A CN1688343A (zh) 2005-10-26
CN1688343B true CN1688343B (zh) 2010-09-08

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038237245A Expired - Fee Related CN1688343B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法
CN2010101825535A Expired - Fee Related CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101825535A Expired - Fee Related CN101863998B (zh) 2002-08-30 2003-09-01 修饰糖、其缀合物及其制备方法

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN1688343B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863998B (zh) * 2002-08-30 2012-08-29 诺华疫苗和诊断有限公司 修饰糖、其缀合物及其制备方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
PT1885734E (pt) * 2005-05-06 2015-03-04 Novartis Ag Imunogénios para vacinas contra a meningite-a
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2010027499A2 (en) 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BR122019005883A8 (pt) * 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP2017505792A (ja) * 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
EP3270959A1 (en) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis compositions and methods thereof
BR112018068523A2 (pt) * 2016-03-15 2019-01-22 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
PT3506935T (pt) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
KR20190121330A (ko) * 2017-02-24 2019-10-25 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
KR102734995B1 (ko) 2017-09-07 2024-11-26 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CN114126662A (zh) * 2019-03-08 2022-03-01 葛兰素史克生物有限公司 碳环衍生物及其缀合衍生物以及其在疫苗中的用途
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
NZ331578A (en) * 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
JP4182269B2 (ja) * 1997-08-08 2008-11-19 ベーリングウエルケ、アクティエンゲゼルシャフト 生体分子のポリサッカライド接合体
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
DK1490409T3 (da) 2002-03-26 2009-03-23 Novartis Vaccines & Diagnostic Modificerede saccharider med forbedret stabilitet i vand
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863998B (zh) * 2002-08-30 2012-08-29 诺华疫苗和诊断有限公司 修饰糖、其缀合物及其制备方法

Also Published As

Publication number Publication date
US20150166593A1 (en) 2015-06-18
GB0220198D0 (en) 2002-10-09
NZ538703A (en) 2006-09-29
EP1534342A1 (en) 2005-06-01
DE60303961D1 (de) 2006-05-04
JP5314745B2 (ja) 2013-10-16
AU2003260921B2 (en) 2008-03-06
ES2260682T3 (es) 2006-11-01
AU2003260921A1 (en) 2004-03-19
JP5268222B2 (ja) 2013-08-21
BR0314089A (pt) 2005-11-16
RU2531909C2 (ru) 2014-10-27
CA2497167C (en) 2011-07-12
US20060263390A1 (en) 2006-11-23
CA2497167A1 (en) 2004-03-11
JP2006511465A (ja) 2006-04-06
WO2004019992A1 (en) 2004-03-11
DE60303961T2 (de) 2006-10-26
DK1534342T3 (da) 2006-07-10
RU2005108992A (ru) 2005-11-10
JP2012017342A (ja) 2012-01-26
RU2008150551A (ru) 2010-06-27
CN1688343A (zh) 2005-10-26
ATE319481T1 (de) 2006-03-15
US8895516B2 (en) 2014-11-25
CN101863998A (zh) 2010-10-20
EP1534342B1 (en) 2006-03-08
MXPA05002315A (es) 2005-06-08
CN101863998B (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
CN1688343B (zh) 修饰糖、其缀合物及其制备方法
EP1777236B1 (en) Modified saccharides having improved stability in water for use as a medicament
EP2184071B1 (en) Capsular polysaccharide solubilisation and combination vaccines
EP1587538B1 (en) Mucosal meningococcal vaccines
EP2258717A2 (en) Variant form of meningococcal NadA
CN100491403C (zh) 具有改善的水中稳定性的修饰的糖类
AU2003216633B2 (en) Modified saccharides having improved stability in water

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20170728

Address after: Belgium Sutter Rixon

Patentee after: Glazo Smithkline Beecham Biologicals S. A.

Address before: Italy Siena

Patentee before: Novartis Vaccines & Diagnostic

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100908

Termination date: 20180901

CF01 Termination of patent right due to non-payment of annual fee